Inlyta (axitinib)

News alerts, weekly reports and conference planners

Company:

Pfizer

Drug class:

VEGFR inhibitor

Related drugs:

‹

›

No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1	avelumab + axitinib Sensitive: A1 - Approval avelumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1	pembrolizumab + axitinib Sensitive: A1 - Approval pembrolizumab + axitinib Sensitive : A1
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1	axitinib Sensitive: A1 - Approval axitinib Sensitive : A1
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Clear Cell Renal Cell Carcinoma	No biomarker	Clear Cell Renal Cell Carcinoma	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2
No biomarker	Soft Tissue Sarcoma	No biomarker	Soft Tissue Sarcoma	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2	pembrolizumab + axitinib Sensitive: A2 - Guideline pembrolizumab + axitinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2	axitinib Sensitive: A2 - Guideline axitinib Sensitive : A2
No biomarker	Kidney Cancer	No biomarker	Kidney Cancer	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2	avelumab + axitinib Sensitive: A2 - Guideline avelumab + axitinib Sensitive : A2
PD-L1 expression	Clear Cell Renal Cell Carcinoma	PD-L1 expression	Clear Cell Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: B - Late Trials pembrolizumab + axitinib Sensitive : B	pembrolizumab + axitinib Sensitive: B - Late Trials pembrolizumab + axitinib Sensitive : B
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	avelumab + axitinib Sensitive: B - Late Trials avelumab + axitinib Sensitive : B	avelumab + axitinib Sensitive: B - Late Trials avelumab + axitinib Sensitive : B
PD-L1 expression	Renal Cell Carcinoma	PD-L1 expression	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: B - Late Trials pembrolizumab + axitinib Sensitive : B	pembrolizumab + axitinib Sensitive: B - Late Trials pembrolizumab + axitinib Sensitive : B
HLA-A*03	Renal Cell Carcinoma	HLA-A*03	Renal Cell Carcinoma	avelumab + axitinib Resistant: B - Late Trials avelumab + axitinib Resistant : B	avelumab + axitinib Resistant: B - Late Trials avelumab + axitinib Resistant : B
No biomarker	Renal Cell Carcinoma	No biomarker	Renal Cell Carcinoma	toripalimab-tpzi + axitinib Sensitive: B - Late Trials toripalimab-tpzi + axitinib Sensitive : B	toripalimab-tpzi + axitinib Sensitive: B - Late Trials toripalimab-tpzi + axitinib Sensitive : B
PD-L1 expression	Melanoma	PD-L1 expression	Melanoma	toripalimab-tpzi + axitinib Sensitive: C2 – Inclusion Criteria toripalimab-tpzi + axitinib Sensitive : C2	toripalimab-tpzi + axitinib Sensitive: C2 – Inclusion Criteria toripalimab-tpzi + axitinib Sensitive : C2
PAI1 elevation	Renal Cell Carcinoma	PAI1 elevation	Renal Cell Carcinoma	axitinib Resistant: C3 – Early Trials axitinib Resistant : C3	axitinib Resistant: C3 – Early Trials axitinib Resistant : C3
CEACAM1 overexpression	Renal Cell Carcinoma	CEACAM1 overexpression	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: C3 – Early Trials pembrolizumab + axitinib Sensitive : C3	pembrolizumab + axitinib Sensitive: C3 – Early Trials pembrolizumab + axitinib Sensitive : C3
CXCL10 overexpression	Renal Cell Carcinoma	CXCL10 overexpression	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: C3 – Early Trials pembrolizumab + axitinib Sensitive : C3	pembrolizumab + axitinib Sensitive: C3 – Early Trials pembrolizumab + axitinib Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	palbociclib + avelumab + axitinib Sensitive: C3 – Early Trials palbociclib + avelumab + axitinib Sensitive : C3	palbociclib + avelumab + axitinib Sensitive: C3 – Early Trials palbociclib + avelumab + axitinib Sensitive : C3
IL6 elevation	Renal Cell Carcinoma	IL6 elevation	Renal Cell Carcinoma	pembrolizumab + axitinib Resistant: C3 – Early Trials pembrolizumab + axitinib Resistant : C3	pembrolizumab + axitinib Resistant: C3 – Early Trials pembrolizumab + axitinib Resistant : C3
FH deletion	Renal Cell Carcinoma	FH deletion	Renal Cell Carcinoma	sintilimab + axitinib Sensitive: C3 – Early Trials sintilimab + axitinib Sensitive : C3	sintilimab + axitinib Sensitive: C3 – Early Trials sintilimab + axitinib Sensitive : C3
TMB-H	Urothelial Cancer	TMB-H	Urothelial Cancer	avelumab + axitinib Sensitive: C3 – Early Trials avelumab + axitinib Sensitive : C3	avelumab + axitinib Sensitive: C3 – Early Trials avelumab + axitinib Sensitive : C3
TMB-L	Non Small Cell Lung Cancer	TMB-L	Non Small Cell Lung Cancer	avelumab + axitinib Sensitive: C3 – Early Trials avelumab + axitinib Sensitive : C3	avelumab + axitinib Sensitive: C3 – Early Trials avelumab + axitinib Sensitive : C3
LDH elevation	Renal Cell Carcinoma	LDH elevation	Renal Cell Carcinoma	axitinib Resistant: C3 – Early Trials axitinib Resistant : C3	axitinib Resistant: C3 – Early Trials axitinib Resistant : C3
BCR-ABL1 T315L	Acute Lymphocytic Leukemia	BCR-ABL1 T315L	Acute Lymphocytic Leukemia	axitinib Sensitive: C4 – Case Studies axitinib Sensitive : C4	axitinib Sensitive: C4 – Case Studies axitinib Sensitive : C4
PBRM1 mutation + SETD2 mutation	Renal Cell Carcinoma	PBRM1 mutation + SETD2 mutation	Renal Cell Carcinoma	temsirolimus + axitinib Sensitive: C4 – Case Studies temsirolimus + axitinib Sensitive : C4	temsirolimus + axitinib Sensitive: C4 – Case Studies temsirolimus + axitinib Sensitive : C4
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	axitinib Sensitive: C4 – Case Studies axitinib Sensitive : C4	axitinib Sensitive: C4 – Case Studies axitinib Sensitive : C4
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	dasatinib + axitinib Sensitive: C4 – Case Studies dasatinib + axitinib Sensitive : C4	dasatinib + axitinib Sensitive: C4 – Case Studies dasatinib + axitinib Sensitive : C4
SETD2 mutation + TP53 mutation	Renal Cell Carcinoma	SETD2 mutation + TP53 mutation	Renal Cell Carcinoma	pembrolizumab + axitinib Sensitive: C4 – Case Studies pembrolizumab + axitinib Sensitive : C4	pembrolizumab + axitinib Sensitive: C4 – Case Studies pembrolizumab + axitinib Sensitive : C4
CCNE1 amplification	Renal Cell Carcinoma	CCNE1 amplification	Renal Cell Carcinoma	axitinib Resistant: D – Preclinical axitinib Resistant : D	axitinib Resistant: D – Preclinical axitinib Resistant : D
BRAF V600E	Thyroid Gland Anaplastic Carcinoma	BRAF V600E	Thyroid Gland Anaplastic Carcinoma	PLX4720 + axitinib Sensitive: D – Preclinical PLX4720 + axitinib Sensitive : D	PLX4720 + axitinib Sensitive: D – Preclinical PLX4720 + axitinib Sensitive : D

Inlyta (axitinib)

Associations
(34)

Associations
(34)

Inlyta (axitinib)

Associations(34)

Associations(34)

Associations
(34)

Associations
(34)